Amgen pleads guilty to misbranding charges, will pay $762 million

NEW YORK (Reuters) - Amgen Inc pleaded guilty in a federal court in New York on Tuesday to misbranding its Aranesp anemia drug and agreed to pay $762 million in a civil settlement and criminal fines.

via Reuters: Health News Read More Here..